Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

Technology appraisal guidance
Reference number: TA217
Published: 23 March 2011
Last updated: 20 June 2018

History

Background information

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review decision - April 2015 information
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015 (PDF 120 KB)

Published:

27 April 2015
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review proposal - April 2014 information
Appendix A - provisional matrix of stakeholders (PDF 98 KB)

Published:

23 April 2014
Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 873 KB)

Published:

23 April 2014
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: press release information
2011/047 NICE guidance extends recommendations on Alzheimer's drugs (PDF 89 KB)

Published:

06 December 2013

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development (PDF 74 KB)

Published:

29 March 2011

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination information
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination (PDF 362 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response to comments on the appraisal consultation (PDF 471 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the appraisal consultation
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Eisai/Pfizer (PDF 53 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Lundbeck (PDF 127 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the executable model from Lundbeck (PDF 16 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Novartis (PDF 85 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Shire (PDF 57 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Alzheimer's Society (PDF 97 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Association of British Neurologists (PDF 150 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from British Geriatrics Society (PDF 88 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Nursing (PDF 66 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Psychiatrists (PDF 125 KB)

Published:

18 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert comment on the appraisal consultation from Dr Peter Connelly (PDF 42 KB)

Published:

17 January 2011
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the ACD received through the NICE website (PDF 247 KB)

Published:

18 January 2011

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation document information
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): evaluation report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model A (PDF 4.31 MB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model B (PDF 2.18 MB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): additional analysis for PenTAG (PDF 35 KB)

Published:

07 January 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAG new results (PDF 1.29 MB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAGs parameters in the Lundbeck model (PDF 50 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): consultee and commentator comments on the assessment report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from the Research Institute for the Care of Older People (PDF 81 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Shire (PDF 85 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Novartis (PDF 104 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS Quality Improvement Scotland (PDF 129 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS West Kent (PDF 68 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): commments from the Alzheimer's Society (PDF 173 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Eisai Ltd/Pfizer Ltd (joint response) (PDF 583 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck (PDF 873 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): non-manufacturer submission
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Alzheimer's Society (part 1) (PDF 372 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): British Geriatrics Society (PDF 160 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Royal College of Psychiatrists (PDF 212 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): manufacturer full submissions
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Eisai Ltd/Pfizer Ltd (joint submission) (PDF 924 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck UK (PDF 999 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Shire Pharmaceuticals (PDF 134 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response from Peninsula Technology Assessment Group (PenTAG) (PDF 290 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert written personal statements
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Connelly (PDF 123 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Hill (PDF 54 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Simmons (PDF 62 KB)

Published:

07 October 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): overview (PDF 612 KB)

Published:

07 October 2010

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 1) (PDF 4.31 MB)

Published:

14 July 2010
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 2) (PDF 2.15 MB)

Published:

14 July 2010

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol (PDF 112 KB)

Published:

20 January 2010

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix (PDF 30 KB)

Published:

07 December 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope (PDF 46 KB)

Published:

20 November 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix (PDF 30 KB)

Published:

20 November 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope (PDF 231 KB)

Published:

20 November 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix (PDF 30 KB)

Published:

24 September 2009

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope (PDF 50 KB)

Published:

24 September 2009